<< Dental neglect may indicate wider child neglect and abuse | SFDA approves China Pharma Holdings' generic Omeprazole Sodium injection >>

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Finnish | Русский | Polski

FDA places Geron Corporation's IND for spinal cord injury on clinical hold

Published on August 19, 2009 at 4:17 AM · No Comments

Geron Corporation (Nasdaq:GERN) today announced that its IND (Investigational New Drug application) for GRNOPC1, a cell therapy for neurologically complete, subacute spinal cord injury, has been placed on clinical hold by the FDA pending the agency’s review of new nonclinical animal study data submitted by the company. A clinical hold is an order that the FDA issues to a sponsor to delay a proposed trial or to suspend an ongoing trial.

Since filing the IND, Geron has been undertaking studies to enable dose escalation of its spinal cord injury product, and has been investigating application of the product to other neurodegenerative diseases. The company has also been performing additional product characterization and conducting further animal studies. Data from this work has been submitted to the FDA. Geron will work closely with the FDA to facilitate their review of the new data and to release the clinical hold. No patients have yet been treated in this study.

6e9711d0-64ab-4540-b134-dc1ea4fa686d|11|4.9

Posted in: Miscellaneous News | Miscellaneous News | Pharmaceutical News | Pharmaceutical News

Tags: Cancer, Cancer, Cell, Cell, Diabetes, Diabetes, Embryonic Stem Cell, Embryonic Stem Cell, Heart Failure, Heart Failure, New Drug Application, New Drug Application, Spinal Cord Injury, Spinal Cord Injury, Stem Cell, Stem Cell, Vaccine, Vaccine

Related posts

Mylan confirms generic Generess Fe patent challengeMylan Inc. today confirmed that it and Famy Care Ltd. have been sued by Warner Chilcott Company LLP,...
Much work remains to be done in fight against malariaPositive results announced this week from a large clinical trial testing the efficacy of the RTS,S m...
Olive oil may help prevent stroke in older peopleA new study suggests that consuming olive oil may help prevent a stroke in older people. The researc...
Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year...
Drugs against protective action of bacteria's antitoxin moleculesBacteria often attack with toxins designed to hijack or even kill host cells. To avoid self-destruct...
Interaction of light with circadian systemsIn a new paper published this week in the Proceedings of the National Academy of Sciences, Aziz Sanc...
Stem cell biology offers great hope for eventual repair of body partsRemarkable progress in understanding how stem cell biology works has been reported by a team of lead...
Relypsa announces positive results from Phase 2 clinical trial of RLY5016Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced ...
Researchers unveil protection mechanism of telomeres from DNA repairIn the latest issue of the journal Nature, Miguel Godinho Ferreira, Principal Investigator at the In...
ImPACKD, The Kidney Foundation of Canada launch online resource for CKD patientsBefore today, millions of Canadians living with chronic kidney disease did not have a strong online ...
Maven Semantic announces updates to Bioinformatics medical professionals databaseMaven Semantic announces updates to their Bioinformatics database.
Biodel submits NDA to FDA for clearance to market VIAjectBiodel, Inc. announced today that it has submitted a new drug application (NDA) to the U.S. Food and...
Vivakor launches new website to promote its remarkable VivaThermic VialVivakor, Inc. today announced the launch of its new website promoting its remarkable VivaThermic Via...
Patients on immunosuppressant medication can receive H1N1 vaccine in the form of shotsThe Centers for Disease Control and Prevention (CDC) have classified all children, 6-months to 24-ye...
FDA places Geron Corporation's IND for spinal cord injury on clinical holdGeron Corporation (Nasdaq:GERN) today announced that its IND (Investigational New Drug application) ...
Breast cancer cells have to learn to walk before they can runEarly-stage breast cancer that has not yet invaded the surrounding tissues may already contain highl...
Analysis of diabetes drugsMost oral medications prescribed for type 2 diabetes are similarly effective for reducing blood gluc...
Breakthrough in brain injury study at University of LeicesterA breakthrough by scientists at the University of Leicester in understanding mechanisms within the b...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.